The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 77K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sparer, T. E.
Right arrow Articles by Openshaw, P. J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sparer, T. E.
Right arrow Articles by Openshaw, P. J.M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/6/1921/ $5.00
The Journal of Experimental Medicine, Volume 187, Number 11, June 1, 1998 1921-1926


Brief Definitive Reports

Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia

Tim E. Sparer*, Stephen Matthews*, Tracy Hussell*, Aaron J. Rae*, Blanca Garcia-Barreno{ddagger}, Jose A. Melero{ddagger}, and Peter J.M. Openshaw*

From the * Imperial College School of Medicine, National Heart and Lung Institute at St. Mary's, London, W2 1PG United Kingdom; and the {ddagger} Centro Nacional de Biologìa Celular y Retrovirus, Instituto de Salud ‘Carlos III', Majadahonda, 28220, Madrid, Spain

In a murine model of respiratory syncytial virus disease, prior sensitization to the attachment glycoprotein (G) leads to pulmonary eosinophilia and enhanced illness. Three different approaches were taken to dissect the region of G responsible for enhanced disease and protection against challenge. First, mutant viruses, containing frameshifts that altered the COOH terminus of the G protein, were used to challenge mice sensitized by scarification with recombinant vaccinia virus (rVV) expressing wild-type G. Second, cDNA expressing these mutated G proteins were expressed by rVV and used to vaccinate mice before challenge with wild-type respiratory syncytial virus (RSV). These studies identified residues 193–205 to be responsible for G-induced weight loss and lung eosinophilia and showed that this region was not was not necessary for induction of protective immunity. Third, mice were sensitized using an rVV that expressed only amino acids 124–203 of the G protein. Upon RSV challenge, mice sensitized with this rVV developed enhanced weight loss and eosinophilia. This is the first time that a region within RSV (amino acids 193–203) has been shown to be responsible for induction of lung eosinophilia and disease enhancement. Moreover, we now show that it is possible to induce protective immunity with an altered G protein without inducing a pathological response.

Key Words: respiratory syncytial virus • G protein • eosinophilia • vaccine • T helper cell


Address correspondence to Peter Openshaw, Imperial College School of Medicine, National Heart and Lung Institute at St. Mary's, Norfolk Place, London, W2 1PG United Kingdom. Phone: 44-0171-594-3854; Fax: 44-0171-724-7349; E-mail: p.openshaw{at}ic.ac.uk

T.E. Sparer and S. Matthews contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS